Pharmacokinetics of Ghrelin
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00116025|
Recruitment Status : Completed
First Posted : June 27, 2005
Last Update Posted : February 28, 2007
|Condition or disease||Intervention/treatment|
|Healthy Subjects||Drug: Human acylated ghrelin|
Ghrelin is a recently described acylated peptide hormone produced by the enteroendocrine cells of the mucosal epithelial layer in the ventricle. Ghrelin is the endogenous ligand for the growth hormone (GH) secretagogue receptor (GHS-R).
Ghrelin stimulates pituitary GH release by binding to the GHS-R at both hypothalamic and pituitary levels.
Several studies show that bolus injections of ghrelin have positive effects on cardiac function in healthy humans as well as in humans with cardiac disease. We investigate the changes in cardiac function during ghrelin infusion in healthy subjects.
The pharmacokinetics of ghrelin is described in few studies only, and we aim to elucidate this aspect further.
Comparisons: In a double blind, placebo controlled, cross over study we investigate the effect of 180 minutes ghrelin infusion on 1. cardiac function (tissue Doppler, stroke-velocity index), 2. vascular tone (a. brachialis dilatation), 3. ghrelin-half-life (acylated and des-acylated) and other pharmacokinetic parameters and 4. effect on appetite.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||17 participants|
|Intervention Model:||Crossover Assignment|
|Official Title:||Pharmacokinetics of Ghrelin in Normal Subjects|
|Study Start Date :||March 2005|
|Estimated Study Completion Date :||January 2006|
- Human ghrelin half life in healthy subjects
- Cardiovascular indices (stroke-velocity index, TEI-index)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00116025
|Aarhus University Hospital|
|Aarhus, Denmark, 8000|
|Principal Investigator:||Jens Otto L Jorgensen, DrMedSc||Aarhus University Hospital|